Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2

Inclusion Criteria:

- Male or female ≥ 18 to ≤ 80 years of age

- National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III)
Framingham risk score of 10% or less

- Fasting LDL-C ≥ 100 mg/dL (2.6 mmol/L) and <190 mg/dL

- Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)

Exclusion Criteria:

- History of coronary heart disease

- New York Heart Association (NYHA) III or IV heart failure

- Uncontrolled cardiac arrhythmia

- Uncontrolled hypertension

- Diabetes mellitus (Type 1 diabetes, poorly controlled type 2 diabetes)

- Uncontrolled hypothyroidism or hyperthyroidism